U.S. NIH Turbo Charges India’s COVID-19 Vaccine

In COVID-19, Latest News by Precision Vaccinations

An adjuvant developed with funding from the National Institutes of Health (NIH) has contributed to the success of the Covaxin COVID-19 vaccine, which roughly 25 million people have already received in India and elsewhere.
Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine’s effectiveness. Covaxin was developed and is manufactured in India by Bharat Biotech, stated the NIH on June 29, 2021.

Read More